Page 101 - Human Use News Today

AstraZeneca granted PDUFA extension to allow further time for a full review on Lynparza

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces data, including new evidence, from an...

Dupixent®, the first and only targeted medicine for prurigo nodularis (PN) has been approved by the EC for adults with moderate-to-severe PN.

Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and OlderDec 13, 2022- First and only medication approved in both the U.S. and Europe to treat cholestatic pruritus in patients with Alagille...

The EC has approved Pluvicto® as the first targeted radioligand therapy for advanced prostate cancer, based on Phase III trial results.

Horizon Therapeutics plc (NASDAQ: HZNP): NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT

Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium, Dec. 10, 2022 (GLOBE NEWSWIRE) -- The...

Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union.

Continuous manufacturing offers productivity and cost-saving benefits among other things, but technical and regulatory challenges have slowed uptake....

L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...